Search

BackgroundLimited information currently exists regarding the clinical progression and outcomes of cats that undergo choledochal stenting as a treatment for extrahepatic biliary obstruction (EHBO).Hypothesis/objectivesDescribe clinical characteristics, indications for choledochal stent placement, procedure, and outcomes in a cohort of cats undergoing choledochal stenting and evaluate risk factors associated with survival as well as recurrence of EHBO in affected cats.AnimalsTwenty-three client-owned cats undergoing choledochal stent placement.MethodsRetrospective study. Medical records from 6 academic institutions were reviewed, and data were extracted and analyzed statistically.ResultsMedian age of cats was 10.1 years (range, 2-16), and all cats had at least 2 clinical signs. Most common clinical signs were vomiting in 20/22 (90.9%), inappetence in 19/22 (86.4%), and lethargy in 19/23 (82.6%). Procedural complications were uncommon and rarely related to the stenting procedure. Clinical signs improved postoperatively in 15/20 (75.0%) cats and serum total bilirubin concentration decreased postoperatively in 13/19 (68.4%) cats. Eighteen (78.3%) cats survived to discharge. Recurrence of EHBO was documented in 7/18 (38.9%) cats that survived to discharge. Cholelithiasis was associated with recurrence of EHBO. Median survival time for cats that survived to discharge was 931 days (range, 19-3034). Absence of peritoneal effusion was associated with survival to discharge.Conclusions and clinical importanceCholedochal stenting was an effective treatment modality in cats with EHBO with few procedural complications and potential for prolonged survival, but substantial risk for recurrence of EHBO was identified.

PurposeThe mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth of distant metastases. In this study, pet dogs with appendicular osteosarcoma were leveraged as high-value biologic models for pediatric osteosarcoma, to assess mTOR inhibition as a therapeutic strategy for attenuating metastatic disease progression.Patients and methodsA total of 324 pet dogs diagnosed with treatment-naïve appendicular osteosarcoma were randomized into a two-arm, multicenter, parallel superiority trial whereby dogs received amputation of the affected limb, followed by adjuvant carboplatin chemotherapy ± oral sirolimus therapy. The primary outcome measure was disease-free interval (DFI), as assessed by serial physical and radiologic detection of emergent macroscopic metastases; secondary outcomes included overall 1- and 2-year survival rates, and sirolimus pharmacokinetic variables and their correlative relationship to adverse events and clinical outcomes.ResultsThere was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.ConclusionsIn a population of pet dogs nongenomically segmented for predicted mTOR inhibition response, sequentially administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend DFI or survival in dogs with appendicular osteosarcoma.

The updated VCOG-CTCAE v2 guidelines contain several important updates and additions since the last update (v1.1) was released in 2011 and published within Veterinary and Comparative Oncology in 2016. As the Veterinary Cooperative Oncology Group (VCOG) is no longer an active entity, the original authors and contributors to the VCOG-CTCAE v1.0 and v1.1 were consulted for input, and additional co-authors sought for expansion and refinement of the adverse event (AE) categories. VCOG-CTCAE v2 includes expanded neurology, cardiac and immunologic AE sections, and the addition of procedural-specific AEs. It is our intent that, through inclusion of additional authors from ACVIM subspecialties and the American College of Veterinary Surgery, that we can more comprehensively capture AEs that are observed during clinical studies conducted across a variety of disease states, clinical scenarios, and body systems. It is also our intent that these updated veterinary CTCAE guidelines will offer improved application and ease of use within veterinary practice in general, as well as within clinical trials that assess new therapeutic strategies for animals with a variety of diseases. Throughout the revision process, we strived to ensure the grading structure for each AE category was reflective of the decision-making process applied to determination of dose-limiting events. As phase I trial decisions are based on these criteria and ultimately determine the maximally tolerated dose, there is impact on standard dosing recommendations for any new drug registration or application. This document should be updated regularly to reflect ongoing application to clinical studies carried out in veterinary patients.

BackgroundLower urinary tract transitional cell carcinoma (TCC) is an important but rarely described disease of cats.ObjectivesTo report the clinical characteristics, treatments, and outcomes in a cohort of cats with lower urinary tract TCC and to test identified variables for prognostic relevance.AnimalsOne-hundred eighteen client-owned cats with lower urinary tract carcinoma.MethodsMedical records were retrospectively reviewed to obtain information regarding clinical characteristics, treatments, and outcomes. Recorded variables were analyzed statistically.ResultsMedian age of affected cats was 15 years (range, 5.0-20.8 years) and median duration of clinical signs was 30 days (range, 0-730 days). The trigone was the most common tumor location (32/118; 27.1%) as assessed by ultrasound examination, cystoscopy, or both. Treatment was carried out in 73 of 118 (61.9%) cats. Metastatic disease was documented in 25 of 118 (21.2%) cats. Median progression-free survival and survival time for all cats were 113 days (95% confidence interval [CI], 69-153) and 155 days (95% CI, 110-222), respectively. Survival increased significantly (P

Copyright of Canadian Veterinary Journal / Revue Vétérinaire Canadienne is the property of Canadian Veterinary Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A 13-year-old spayed female Cairn terrier was referred for surgical resection of a large oesophageal mass. The dog was initially presented to the primary care veterinarian for several days of gagging. The mass was initially diagnosed on thoracic radiographs and confirmed via computed tomography and oesophagoscopy. Endoscopic biopsies were performed that were consistent with oesophagitis. The dog was then referred to The Ohio State University Veterinary Medical Center for surgical resection of the mass. On surgical approach, a small nodule was palpable in the oesophagus; however, a large mass was not found. Oesophagoscopy was repeated intraoperatively, which revealed a small nodule in the same region of the previously described mass. The small nodule was removed, and histopathology was consistent with lymphohistiocytic inflammation and previous haemorrhage, consistent with an oesophageal haematoma. The dogmade a full recovery post-operatively, with continued resolution of clinical signs reported 5months after surgery. [ABSTRACT FROM AUTHOR]

Copyright of Canadian Veterinary Journal / Revue Vétérinaire Canadienne is the property of Canadian Veterinary Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE To evaluate colonoscopic and histologic features of rectal masses in dogs. DESIGN Retrospective case series. ANIMALS 82 client-owned dogs with rectal masses that underwent colonoscopy. PROCEDURES Medical records of dogs with rectal masses that underwent colonoscopy were reviewed. History, signalment, clinical signs, results of physical examination, diagnostic imaging findings, and results of colonoscopy (including complications) were recorded. When available, tissue samples obtained during colonoscopy and by means of surgical biopsy were reviewed by a single board-certified pathologist. Histologic features and tumor grade (when applicable) of tissue samples obtained during colonoscopy versus surgical biopsy were compared. RESULTS Multiple rectal masses were observed during colonoscopy in 6 of the 82 dogs, but no lesions were visualized orad to the colorectal junction. Results of histologic evaluation of surgical biopsy specimens were consistent with a diagnosis of epithelial neoplasia in 58 of 64 dogs, of which 71% were classified as benign adenoma or polyp and 29% were classified as adenocarcinoma in situ or adenocarcinoma. Complications of colonoscopy occurred in 3 of 82 dogs but were considered minor. A discrepancy in diagnosis occurred in 5 of 16 dogs for which both colonoscopic and surgical biopsy samples were available for histologic review. CONCLUSIONS AND CLINICAL RELEVANCE Results suggested that multiple rectal masses are uncommon in dogs, and secondary lesions orad to the colorectal junction were not found in this study. Colonoscopy was associated with few complications, but the need for colonoscopic assessment of the entire colon in this patient population may merit reevaluation.

A 9‐year‐old, female, spayed American Pitbull terrier presented for a month‐long history of lethargy, inappetence, altered breathing and unusual tongue movement. Severe anaemia was noted on bloodwork. Oral exam revealed an exophytic, pale, tan mass at the tongue base. A computed tomography scan was performed, followed by surgical removal of the mass. Histopathology confirmed the mass as an extramedullary plasmacytoma. Within 24 hours of removal, the clinical signs and anaemia were improving, and the dog was released from hospital. On follow‐up 2 weeks postoperatively, the dog's bloodwork was all within normal parameters, the anaemia was completely resolved, and the dog was doing well at home. After 692 days of successful removal of the tumour, the owner reports the dog is doing well at home. [ABSTRACT FROM AUTHOR]

Primary hepatic neuroendocrine carcinoma, previously referred to as carcinoid, is a malignant tumour arising from neuroendocrine cells and is a rare form of hepatic neoplasia in cats. This case report describes primary hepatic neuroendocrine carcinoma in a cat, with weight loss and vomiting as its primary clinical signs. Definitive diagnosis was made following surgical excision and histopathology of the affected liver lobes in addition to immunohistochemistry staining. Following surgery, the cat received different chemotherapy agents due to observation of progressive disease at restaging visits. The cat is currently receiving metronomic chemotherapy of cyclophosphamide and has no evidence of metastatic disease present 1009 days after initial presentation. Primary hepatic neuroendocrine carcinoma can occur in cats and should be a differential diagnosis for a hepatic mass in this species. Primary hepatic neuroendocrine carcinomas are rare in cats, and there is no standard of care for treatment in companion animals. [ABSTRACT FROM AUTHOR]

Background: The most common haemostatic abnormality in dogs with cancer is hypercoagulability. A transient hypercoagulability has been documented in people with hepatocellular carcinoma (HCC) that resolves within weeks following hepatic tumour resection. Objective: The objective was to compare the haemostatic status of dogs with liver tumours and healthy control dogs, by comparing coagulation and thromboelastography (TEG) measurements at three time points. Methods: Liver tumour and healthy control dogs receiving surgery for liver lobectomy and ovariohysterectomy, respectively, were prospectively enrolled. All dogs had blood collected at three time points: pre‐operative, 24 h post‐operative and ~2 weeks post‐operative. Haematological and haemostatic values were compared across time points in each group using repeated measures ANOVA tests. Results: Ten and eight dogs were enrolled for the liver and control groups, respectively. Platelet count was significantly higher in the liver group than the control group at all time points, but within the normal range (pre‐operative: 438.7 vs. 300.9 × 109/L, p =.0078; 24 h post‐operative: 416.2 vs. 283.9 × 109/L, p =.0123; 10–14 days post‐operative: 524.6 vs. 317.3 × 109/L, p =.0072). The measure of the overall coagulant state (G‐value) was significantly increased for the liver group compared to the control group at all time points (pre‐operative: 15.6 vs. 8.6 d/sc, p =.0003; 24 h post‐operative: 18.3 vs. 11.2 d/sc, p =.039; 10–14 days post‐operative: 15.1 vs. 9.6 d/sc, p =.015). Conclusion: The liver group was hypercoagulable based on elevated G‐values at all time points compared to the control group. This hypercoagulability was attributed to the effect of hepatic tumours alone, and not secondary to surgery and anaesthesia. [ABSTRACT FROM AUTHOR]

Copyright of Canadian Veterinary Journal / Revue Vétérinaire Canadienne is the property of Canadian Veterinary Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The Veterinary Cancer Guidelines and Protocols (VCGP) group has developed guidelines for developing, reporting, and validating histologic tumor grading systems. These guidelines aim to standardize tumor evaluation in order to improve the care of animals with cancer. The grading systems should be reproducible, relevant to prognosis, and realistic in terms of applicability in a routine diagnostic setting. The VCGP group encourages collaboration from various disciplines and emphasizes the importance of standardized clinical outcomes and statistical assessment. The guidelines also suggest comparing histologic grade with other assays and encourage the publication of grading systems in peer-reviewed journals with sufficient details for replication and validation. Validation studies should be conducted before implementing the grading system on clinical cases. [Extracted from the article]

Copyright of Canadian Veterinary Journal / Revue Vétérinaire Canadienne is the property of Canadian Veterinary Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)